Atrial fibrillation
Conditions
Interventions
Normal volunteer: C-11 hydroxyephedrine (dosage: 185 MBq, only once) Patients with atrial fibrillation: C-11 hydroxyephedrine (dosage: 185 MBq, before and after the therapy)
Sponsors
Department of Cardiology, Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with atrial fibrillation We enrolled the outpatients of the cardiovascular department of Hokkaido University Hospital who satisfy below criteria, 1) who is 20 years or older 2) who is scheduled radiofrequency catheter ablation to atrial fibrillation 3) who is explained well about this study and consent to the study. 2. Normal volunteer We will collect the volunteer who satisfy below criteria. 1) age between 30 to 70 years old 2) who has not been diagnosed cardiac disease 3) who has no symptom such as chest pain 4) who is explained well about this study and consent to this study.
Exclusion criteria
Exclusion criteria: Exclusion criteria is described below 1) who use adrenergic neuron blocking drug regularly 2) claustrophobia 3) patients with atrial fibrillation due to mitral stenosis 4) ischemic heart disease 5) cardiomyopathy 6) chronic heart failure 7) diabetes mellitus 8) dementia 9) advanced chronic kidney disease (eGFR < 30 ml/min/1.73m^2) 10) mechanical device in their body such as pacemaker or clip for aneurysm 11) who can't consent to this study ( (3)-(5) is only adopted to the patients with atrial fibrillation)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare cardiac sympathetic activity in normal volunteer and patients with atrial fibrillation. Compare cardiac sympathetic activity before and after radiofrequency catheter ablation in the patients with atrial fibrillation. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Evaluate the relationship of recurrence of atrial fibrillation and cardiac sympathetic activity in the patients with atrial fibrillation after radiofrequency catheter ablation. 2) Evaluate the relationship of atrial or ventricular fibrosis and cardiac sympathetic activity. | — |
Countries
Japan
Contacts
Public ContactAtsuro Masuda
Hokkaido University Graduate School of Medicine Department of Nuclear Medicine
Outcome results
None listed